DocGo Earnings Call Signals Turnaround Amid Cash Strain

DocGo, Inc. ((DCGO)) has held its Q4 earnings call. Read on for the main highlights of the call.

DocGo’s latest earnings call painted a cautiously optimistic picture, with management highlighting improving operations, stronger-than-expected revenue, and a tighter path to profitability in 2026. At the same time, investors were reminded of sizable noncash write-downs, a sharp year-over-year revenue drop from exiting migrant contracts, and near-term liquidity and covenant risks that could still weigh on the stock.

Revenue Beat and Upgraded 2026 Outlook

DocGo reported Q4 2025 revenue of $74.9 million, topping the high end of its guidance range and underscoring resilience in its core businesses after the migrant program roll-off. Building on that momentum, the company raised its 2026 revenue outlook to $290 million–$310 million, which implies 15%–23% growth over its 2025 base revenue and signals confidence in demand for both transport and mobile health services.

Improved Adjusted EBITDA Trajectory

Management narrowed its expected 2026 adjusted EBITDA loss to $5 million–$10 million from a prior $15 million–$25 million, effectively pulling forward a more favorable profit profile by $10 million–$15 million. The company now expects to reach adjusted EBITDA profitability in the back half of 2026, framing the current year as a transition period where operating leverage and cost controls begin to show through.

SteadyMD Integration and Growth Upside

The recently acquired SteadyMD platform emerged as a key growth pillar, generating more than $8 million in Q4 revenue, of which DocGo recorded $6.1 million due to the October 20 close. Full-year interactions climbed above 4 million, up from roughly 2.5 million in 2024, while SteadyMD’s gross margin improved from about 30% to 37%, and management sees an annual revenue contribution in the $25 million–$30 million range with additional upside.

Record Remote Patient Monitoring Profitability

Remote patient monitoring delivered record Q4 revenue of $4.0 million alongside approximately $830,000 of adjusted EBITDA, highlighting it as one of DocGo’s most profitable lines. Patient counts rose 16% year over year, and management characterized segment margins as north of 50%, with further profitability gains expected in 2026 as scale and automation improve.

Strong Volume Momentum Across Core Services

Operational metrics showed broad-based volume strength, with Q4 medical transportation trips rising 11% and healthcare-in-the-home visits surging 113% versus the prior-year quarter. Mobile phlebotomy volumes climbed 16%, remote patients monitored increased 16%, telehealth and lab orders jumped 50%, and care gap assigned lives grew 12% sequentially to more than 1.45 million, while customer satisfaction remained high with a net promoter score of 92.

Transport Margins and Staffing Efforts

In the transportation segment, adjusted gross margin improved to 32.8% in 2025 from 30.1% in 2024 as the company made progress on staffing and efficiency. DocGo filled 206 of 546 open EMT and paramedic roles, and overtime levels have been trending down from around 13% of hourly wages toward a sub-10% target, a shift that should reduce effective labor costs and support further margin expansion.

Efficiency Initiatives Target Cost Savings

Management highlighted an “efficiency innovation” portfolio of more than a dozen projects, focused on automation and process improvements to drive operating leverage. These initiatives, which include pre-billing automation and integration of AgenTeq for patient outreach, are expected to deliver $5 million–$6 million in cost savings in 2026 and ramp to approximately $20 million–$24 million in annual savings by 2027.

Strategic Alternatives Under Review

Adding a strategic layer to the story, DocGo has launched a formal process to explore alternatives aimed at maximizing shareholder value and has engaged an investment bank to assist. While management did not detail specific options, the move suggests openness to potential transactions or structural changes that could unlock value if the market continues to discount the company’s long-term earnings power.

Revenue Hit from Migrant Program Wind-Down

The headline year-over-year revenue decline was stark, with Q4 2025 revenue of $74.9 million down from $120.8 million in Q4 2024 and full-year revenue falling to $322.2 million from $616.6 million. Management stressed that this contraction was driven entirely by the planned wind-down of migrant-related projects, which still contributed about $7.4 million of low-margin mobile health revenue in Q4.

Ongoing Adjusted EBITDA Losses and Cash Burn

DocGo posted an adjusted EBITDA loss of roughly $11.3 million in Q4 and a full-year 2025 loss of $28.6 million, a meaningful improvement from the $60 million loss in 2024 but still a drag on cash. The company cautioned that operating losses will likely continue in the early part of 2026, implying potential near-term cash declines and underscoring the importance of executing on cost reductions and margin improvements.

Heavy Non-Cash Impairments Cloud GAAP Results

The quarter’s GAAP numbers were heavily distorted by noncash charges, including a $49.5 million goodwill impairment and a $22.6 million write-down of intangible assets to zero, alongside a $5 million impairment of an equity investment. These adjustments reflect lower carrying values relative to the company’s market capitalization rather than current cash outflows but nevertheless underscore how sharply expectations have reset since prior acquisition and investment decisions.

Liquidity Strain and Delayed Receivables

Cash and equivalents fell to $68.3 million at year-end from $95.2 million at the end of Q3, partly due to cash paid for the SteadyMD acquisition but also because of slow-paying migrant-related receivables. Around $20 million of receivables tied to New York City programs remain delayed, and while the company expects eventual collection, the timing uncertainty introduces working capital stress and potential covenant pressure on its credit facilities.

Margin Pressure in Mobile Health and Blended Results

Blended adjusted gross margin in Q4 slipped to 32.5% from 33.5% a year earlier, reflecting mix shifts and the drag from low-margin legacy work. Within mobile health, adjusted gross margin dropped to 31.8% from 35.9% in 2024, in part because migrant projects carried margins below 20% in the quarter, and management is focused on replacing that revenue with higher-quality, more profitable business.

Overtime and Labor Costs Still a Headwind

Elevated overtime levels continue to weigh on transportation profitability, with overtime running roughly 11%–13% of hourly wages in recent quarters and landing at about 13% in Q4. Management reiterated that improving hiring and retention is key to driving overtime down toward high-single-digit or mid-single-digit levels, which should meaningfully lower effective wage rates and support the company’s margin targets.

Credit Line Negotiations and Potential Financing Costs

DocGo is actively negotiating with its credit line provider to address covenant issues that arise from its current financial profile and delayed receivables. While the company has not drawn on the line to date, management acknowledged that any amendments or waivers might come with higher borrowing costs, highlighting that financing terms could tighten even as the business works toward improved profitability.

Forward Guidance and 2026 Roadmap

Looking ahead, DocGo’s guidance calls for 2026 revenue of $290 million–$310 million and an adjusted EBITDA loss narrowed to $5 million–$10 million, underpinned by an assumed blended adjusted gross margin of about 33%. The outlook includes roughly $215 million from transport, $85 million–$88 million from mobile health, $25 million–$30 million from SteadyMD, and $5 million–$6 million of efficiency savings, with the company targeting adjusted EBITDA profitability in the second half as volumes grow, overtime recedes, and high-margin segments like remote patient monitoring scale.

DocGo’s earnings call ultimately sketched a company in transition, shaking off one-time migrant revenues and heavy impairments while building a more diversified and scalable platform. For investors, the story now hinges on whether management can deliver on its operational promises, stabilize liquidity, and convert strong volume and high-margin niches into sustained, cash-backed profitability by late 2026.